Study Evaluating the Safety and Efficacy of MN-221 as an Adjunct to Standard Therapy in Subjects Experiencing an Acute Exacerbation of Asthma
MN-221-CL-007: A Phase II, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of MN-221 When Administered Intravenously as an Adjunct to Standard Therapy to Adults With an Acute Exacerbation of Asthma
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
This is an international, randomized, double-blind, placebo-controlled, multi-center ED study. Each subject will receive MN-221 or placebo administered through a continuous intravenous infusion in addition to the standardized treatment for an acute exacerbation of asthma.
Upon presentation to the ED for assessment and treatment for an acute exacerbation of asthma the patient should receive standard of care consistent with the international guidelines (e.g., Global Initiative for Asthma [GINA] or the National Asthma Education and Prevention Program [NAEPP]) and required, in part, by this protocol prior to screening procedures being performed.
Prior to any study specific treatment or evaluation being performed a subject must have signed an IRB/EC/REB approved consent form. Once the subject has received the initial treatment regimen the subject will be assessed for response to the treatment including spirometry.If the subject meets all entry criteria the subject will be randomized to receive MN-221 or placebo. Throughout the screening process the subject will continue to receive standardized treatment consistent with the appropriate guidelines for the treatment of acute exacerbations of asthma.
Subjects enrolled in the study will receive an intravenous 1-hour infusion of MN-221 study drug or placebo. Subjects receiving MN-221 will be administered a total dose of 1200 μg.
During the study treatment period, the subject may continue to receive standardized treatment and be assessed. The study treatment period will be approximately 3 hours in length. Safety and efficacy will be monitored throughout the treatment period. PK parameters (if applicable) will be obtained from subjects at selected study sites. A blood sample for genomic evaluation will be collected during the treatment period (at participating sites) if the subject consents to the evaluation. An initial 24-hour post-randomization follow-up visit will be completed to evaluate the subject's health status as well as for safety and PK parameters (if applicable). A second follow-up contact will be completed by telephone seven days post-randomization for safety purposes and to evaluate the subject's health status.
A periodic risk/benefit evaluation will be performed by the study's Data Safety Monitoring Board.
Type d'étude
Inscription (Réel)
Phase
- Phase 2
Contacts et emplacements
Lieux d'étude
-
-
California
-
Loma Linda, California, États-Unis, 92354
- Loma Linda University Medical Center
-
San Diego, California, États-Unis, 92037
- UCSD Medical Center - Thornton Hospital
-
San Diego, California, États-Unis, 92103
- UCSD Medical Center
-
Sylmar, California, États-Unis, 91342
- Olive View - UCLA Medical Center
-
-
Illinois
-
Maywood, Illinois, États-Unis, 60153
- Loyola University Medical Center
-
-
Massachusetts
-
Newton, Massachusetts, États-Unis, 02462
- Newton - Wellesley Hospital
-
Springfield, Massachusetts, États-Unis, 01199
- Baystate Medical Center
-
-
Minnesota
-
Minneapolis, Minnesota, États-Unis, 55415
- Hennepin County Medical Center
-
-
Missouri
-
St. Louis, Missouri, États-Unis, 63110
- Washington University School of Medicine
-
-
New Jersey
-
Hackensack, New Jersey, États-Unis, 07601
- Hackensack University Medical Center
-
-
Ohio
-
Cincinnati, Ohio, États-Unis, 45267-0563
- University of Cincinnati
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, États-Unis, 19141
- Albert Einstein Healthcare Network
-
-
Rhode Island
-
Providence, Rhode Island, États-Unis, 02903
- Rhode Island Hospital
-
-
Texas
-
Dallas, Texas, États-Unis, 75390
- University of Texas Southwestern Medical Center
-
-
Virginia
-
Norfolk, Virginia, États-Unis, 23507
- Sentara General Hospital
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
Subjects meeting all of the following criteria will be considered for admission to the study:
- Male or female 18 to 65 years of age, inclusive;
- Self-reported history of physician-diagnosed and treated asthma for ≥ 3 months prior to randomization;
- A diagnosis of an acute exacerbation of asthma upon presentation at the ED as defined by dyspnea and evidence of bronchospasm;
Received the following Standardized Treatment within a 2-hour time window and prior to obtaining the Qualifying Spirometry value(FEV1):
- Supplemental oxygen given to maintain oxygen saturation as measured by pulse oximetry of ≥ 90% as needed;
- Albuterol 5-15mg of albuterol via nebulizer prior to the qualifying spirometry evaluation; simultaneously with
- Ipratropium 0.5-1.5 mg of ipratropium via nebulizer prior to the qualifying spirometry evaluation;
- One dose of corticosteroid of at least 50 mg given orally (prednisone) or intravenously (methylprednisolone) or the equivalent dose of another corticosteroid.
- FEV1 of ≤ 50% of predicted; NOTE: Spirometry to measure the subject's FEV1 expressed as % of predicted within 30 minutes of completing administration of 5 mg (but not more than 15 mg) albuterol and 0.5 mg (but not more than 1.5 mg) of ipratropium..
- Negative urine pregnancy test for all females of child-bearing potential;
- ECG with no dysrhythmias (except sinus tachycardia);
- No clinical or electrocardiographic signs of ischemic heart disease as determined by the Investigator; and
- Legally effective written informed consent obtained prior to starting any mandated study procedures
Exclusion Criteria:
Subjects will be excluded if they meet any of the following criteria:
- Administration of a parenteral (intravenous or subcutaneous) beta agonist (e. g., albuterol, terbutaline, epinephrine) within 6 hours prior to randomization;
- A current or prior diagnosis or suspected diagnosis of COPD or other chronic lung disease other than asthma;
- Presence of pneumonia;
- Presence of significant other respiratory dysfunction such as pneumothorax, pneumomediastinum, or pulmonary edema;
- Known or suspected vocal cord dysfunction syndrome;
- Presence of aspirated foreign body (known or suspected);
- History or any current clinical evidence suggesting cardiomyopathy or congestive heart failure;
- History or presence of tachyarrhythmias, with the exception of sinus tachycardia;
- Heart rate ≥ 140 bpm;
Hypokalemia, defined as subjects with serum potassium level of <2.8 mEq/L (≤2.8 mmol/L) obtained at Screening (local stat lab, blood gas analysis, or other point of care device) with the following exception:
For the subjects using non-potassium-sparing diuretics (i.e. loop-diuretic or thiazide diuretic) without "potassium-sparing diuretics" (e.g., Triamterene or Spironolactone) OR without potassium supplementation of at least KCl 20 mEq/day whose potassium level <3.5 mEq/L (<3.5 mmol/L) at Screening.
- Significant cardiac, renal, hepatic, endocrine, metabolic, neurologic or other systemic disease. A significant disease will be defined as one which, in the opinion of the Investigator, may either put the subject at risk because of participation in the study, or may influence the results of the study or the subject's ability to participate in the trial;
- Self-reported history of greater than 20 pack-yr smoking history;
- Fever ≥ 102.0 ºF (38.9 ºC);
- Uncontrolled hypertension defined as a blood pressure ≥ 170/100 mm Hg (22.7/13.3 kPa);
- Need for immediate intubation, mechanical ventilation, or non-invasive positive pressure ventilation as determined by the Investigator;
- Pregnant or lactating females;
- Participated in another clinical study with an investigational drug within 30 days of randomization;
- Positive urine drug screen for cocaine, methamphetamine or PCP unless, in the Investigator's clinical judgment, a single positive result is explained by exposure to a non-illicit drug product (i.e., is a false positive). For example, phenylpropanolamine or methylphenidate may read positive in a methamphetamine screen; dextromethorphan in a PCP screen.
- Any subject with a known allergy to components of the MN-221 drug product;
- Any subject with a known allergy to other beta agonists;
- Previous exposure to MN-221; or
- Use of theophylline, beta blockers, digoxin, MAO inhibitors, or tricyclic antidepressants within 2 weeks prior to randomization.
Use of non-potassium-sparing diuretics (i.e. Thiazide or Loop-diuretic) without potassium-sparing diuretic OR without potassium supplementation >20 mEq/day within 2 weeks prior to randomization and if serum potassium level at Screening <3.5 mEq/L (<3.5 mmol/L).
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Quadruple
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: 1
MN-221 given i.v.
1-hour infusion a total dose of 1200 μg (40 μg/min for 15 min [600 μg] + 13.3 μg/min for 45 min [600 μg]) as an adjunct to the standard of care for acute exacerbation of asthma.
|
Dose: intravenous 1-hour infusion of MN-221 (total dose 1200 μg) or matching placebo.
Autres noms:
|
|
Comparateur placebo: Placebo
Placebo (Lot #CLO-095) was packaged in identical vials containing only excipients and administered as an i.v.
1-hour infusion with a regimen as described for MN-221.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Délai |
|---|---|
|
The primary efficacy analysis will be based on a change in FEV1, expressed as percent of predicted, at Hour 3 when compared to FEV1, expressed as percent of predicted, at the qualifying/screening timepoint.
Délai: Hour 3
|
Hour 3
|
Mesures de résultats secondaires
Mesure des résultats |
Délai |
|---|---|
|
Change from baseline FEV1 % of predicted (at time points other than Hour 3)
Délai: Hours 1, 2, 3, and 24
|
Hours 1, 2, 3, and 24
|
|
Change from baseline FEV1 (L)
Délai: Hours 1, 2, 3 and 24
|
Hours 1, 2, 3 and 24
|
|
Change from baseline PEFR (L/sec)
Délai: Hours 1, 2, 3 and 24
|
Hours 1, 2, 3 and 24
|
|
Change from baseline PEFR, expressed as percent (%) of predicted
Délai: Hours 1, 2, 3and 24
|
Hours 1, 2, 3and 24
|
|
Improvement in Dyspnea index scale
Délai: Hours 1, 2, 3, 24 and Day 8
|
Hours 1, 2, 3, 24 and Day 8
|
|
Percent of subjects with an improvement in FEV1 ≥ 200cc
Délai: Hours 1, 2, 3 and 24
|
Hours 1, 2, 3 and 24
|
|
Percent of subjects with an improvement in FEV1, % predicted ≥ 5%
Délai: Hours 1, 2, 3 and 24
|
Hours 1, 2, 3 and 24
|
|
Percent of subjects with and improvement in FEV1, % predicted ≥ 10%
Délai: Hours 1, 2, 3 and 24
|
Hours 1, 2, 3 and 24
|
|
Subjects Hospitalized ( within 24 hour from start of study drug infusion)
Délai: Within 24 hours from start of study drug infusion.
|
Within 24 hours from start of study drug infusion.
|
|
Admitted to ICU (within 24 hours from start of study drug infusion)
Délai: Within 24 hours from start of study drug infusion.
|
Within 24 hours from start of study drug infusion.
|
|
Number of albuterol treatments to achieve an increase in FEV1% of predicted ≥ 15%
Délai: Hours 3
|
Hours 3
|
|
Total dose or number of albuterol treatments in first 3 hours following commencement of randomized medication.
Délai: No specific time points
|
No specific time points
|
|
Time to achieve an increase of FEV1% of predicted ≥ 15%
Délai: No specific time points
|
No specific time points
|
|
Time to initial albuterol treatment following the commencement of randomized medication
Délai: No specific time points
|
No specific time points
|
|
Hospital length of stay
Délai: No specific timepoints
|
No specific timepoints
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Directeur d'études: Kazuko Matsuda, MD, MediciNova
Publications et liens utiles
Publications générales
- House SL, Matsuda K, O'Brien G, Makhay M, Iwaki Y, Ferguson I, Lovato LM, Lewis LM. Efficacy of a new intravenous beta2-adrenergic agonist (bedoradrine, MN-221) for patients with an acute exacerbation of asthma. Respir Med. 2015 Oct;109(10):1268-73. doi: 10.1016/j.rmed.2015.08.003. Epub 2015 Aug 14.
- Schneider JE, Lewis LM, Ferguson I, House SL, Liu J, Matsuda K, Johnson K. Repeated dyspnea score and percent FEV1 are modest predictors of hospitalization/relapse in patients with acute asthma exacerbation. Respir Med. 2014 Sep;108(9):1284-91. doi: 10.1016/j.rmed.2014.06.006. Epub 2014 Jul 8.
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- MN-221-CL-007
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
produit fabriqué et exporté des États-Unis.
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .